 |
32 Diseases |  |
9 Trials |
|
9 Trials |  |
795 News |  |
| «12345678910111213» |
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change, Trial primary completion date: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Jun 20, 2017
P3, N=140, Active, not recruiting, Sponsor: AstraZeneca
N=219 --> 140 | Trial primary completion date: Jun 2017 --> Sep 2017
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open, Monotherapy: Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (clinicaltrials.gov) - Jun 8, 2017
P3, N=780, Recruiting, Sponsor: LEO Pharma
N=219 --> 140 | Trial primary completion date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: STRATOS2: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - May 30, 2017
P3, N=856, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=1698 --> 856
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial, Monotherapy: Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (clinicaltrials.gov) - May 18, 2017
P3, N=780, Not yet recruiting, Sponsor: LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial primary completion date: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - May 15, 2017
P2, N=409, Terminated, Sponsor: MedImmune LLC
N=1698 --> 856 Trial primary completion date: Oct 2015 --> May 2015
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial, Monotherapy: Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (clinicaltrials.gov) - Apr 27, 2017
P3, N=780, Not yet recruiting, Sponsor: LEO Pharma
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial primary completion date: A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Apr 12, 2017
P2, N=30, Recruiting, Sponsor: Emma.Guttman
Trial primary completion date: Oct 2015 --> May 2015 Trial primary completion date: Oct 2017 --> Apr 2018
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: STRATOS2: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Mar 24, 2017
P3, N=1698, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Oct 2017 --> Apr 2018 N=770 --> 1698
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Phase classification: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Mar 21, 2017
P2b, N=306, Completed, Sponsor: MedImmune LLC
N=770 --> 1698 Phase classification: P2 --> P2b
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Mar 16, 2017
P3, N=31, Active, not recruiting, Sponsor: AstraZeneca
Phase classification: P2 --> P2b Recruiting --> Active, not recruiting
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Feb 9, 2017
P3, N=218, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting N=120 --> 218
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Feb 6, 2017
P3, N=2246, Active, not recruiting, Sponsor: AstraZeneca
N=120 --> 218 N=1140 --> 2246
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Enrollment change: MESOS: Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (clinicaltrials.gov) - Jan 18, 2017
P2, N=228, Active, not recruiting, Sponsor: AstraZeneca
N=1140 --> 2246 Recruiting --> Active, not recruiting | N=80 --> 228
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial primary completion date: MESOS: Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (clinicaltrials.gov) - Dec 14, 2016
P2, N=80, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=80 --> 228 Trial primary completion date: Dec 2017 --> Jul 2017
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Dec 4, 2016
P3, N=26, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2017 --> Jul 2017 Not yet recruiting --> Recruiting
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial: A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Sep 16, 2016
P3, N=26, Not yet recruiting, Sponsor: AstraZeneca
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: STRATOS2: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Sep 13, 2016
P3, N=770, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Aug 22, 2016
P3, N=120, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change, Trial termination, Trial primary completion date: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Mar 1, 2016
P2, N=409, Terminated, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting N=186 --> 409 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Oct 2015; Early termination of the study due to lack of efficacy.
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Enrollment change: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Feb 29, 2016
P2, N=306, Completed, Sponsor: MedImmune LLC
N=186 --> 409 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Oct 2015; Early termination of the study due to lack of efficacy. Active, not recruiting --> Completed | N=184 --> 306
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P2 trial: A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Feb 17, 2016
P2, N=30, Recruiting, Sponsor: Emma.Guttman
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Trial primary completion date: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Feb 10, 2016
P3, N=1140, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=184 --> 306 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Feb 2017
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Enrollment change: D2212C00002 J-Phase II Study (clinicaltrials.gov) - Dec 11, 2015
P2, N=37, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Feb 2017 Active, not recruiting --> Completed | N=20 --> 37
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: MESOS: Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (clinicaltrials.gov) - Oct 22, 2015
P2, N=80, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=20 --> 37 Not yet recruiting --> Recruiting
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Trial primary completion date: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Sep 30, 2015
P2, N=184, Active, not recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial initiation date: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Aug 20, 2015
P3, N=1140, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015 Initiation date: Jun 2005 --> Jun 2014
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial initiation date: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Jun 16, 2015
P3, N=1140, Recruiting, Sponsor: AstraZeneca
Initiation date: Jun 2005 --> Jun 2014 Initiation date: Jun 2014 --> Jun 2005
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P2 trial: MESOS: Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (clinicaltrials.gov) - May 20, 2015
P2, N=80, Not yet recruiting, Sponsor: AstraZeneca
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Apr 21, 2015
P2, N=186, Active, not recruiting, Sponsor: MedImmune LLC
Initiation date: Jun 2014 --> Jun 2005 Recruiting --> Active, not recruiting
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Mar 2, 2015
P3, N=120, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Feb 26, 2015
P2, N=184, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial primary completion date: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Feb 19, 2015
P3, N=120, Not yet recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Jul 2017
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P2 trial: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P2, N=184, Not yet recruiting, Sponsor: MedImmune LLC
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change, Trial primary completion date: Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis (clinicaltrials.gov) - Jan 22, 2015
P2a, N=147, Completed, Sponsor: AstraZeneca
Trial primary completion date: Apr 2017 --> Jul 2017 N=111 --> 147 | Trial primary completion date: Jun 2013 --> Mar 2013
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: D2212C00002 J-Phase II Study (clinicaltrials.gov) - Dec 19, 2014
P2, N=20, Active, not recruiting, Sponsor: AstraZeneca
N=111 --> 147 | Trial primary completion date: Jun 2013 --> Mar 2013 Recruiting --> Active, not recruiting
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open, Enrollment change: STRATOS2: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Dec 6, 2014
P3, N=770, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=2200 --> 770
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change, Trial primary completion date: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Nov 3, 2014
P2, N=186, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting | N=2200 --> 770 N=302 --> 186 | Trial primary completion date: Feb 2017 --> Jun 2016
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial: TROPOS: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma (clinicaltrials.gov) - Nov 3, 2014
P3, N=120, Not yet recruiting, Sponsor: AstraZeneca
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Oct 2, 2014
P3, N=1140, Recruiting, Sponsor: AstraZeneca
N=302 --> 186 | Trial primary completion date: Feb 2017 --> Jun 2016 N=2329 --> 1140
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: D2212C00002 J-Phase II Study (clinicaltrials.gov) - Sep 29, 2014
P2, N=20, Recruiting, Sponsor: AstraZeneca
N=2329 --> 1140 N=30 --> 20
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Sep 4, 2014
P3, N=2329, Recruiting, Sponsor: AstraZeneca
N=30 --> 20 N=3250 --> 2329
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial primary completion date: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Jul 23, 2014
P2, N=302, Recruiting, Sponsor: MedImmune LLC
N=3250 --> 2329 Trial primary completion date: Jan 2016 --> Feb 2017
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial: STRATOS2: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Jul 18, 2014
P3, N=2200, Not yet recruiting, Sponsor: AstraZeneca
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers (clinicaltrials.gov) - Jul 1, 2014
P1, N=149, Completed, Sponsor: MedImmune LLC
Trial primary completion date: Jan 2016 --> Feb 2017 N=60 --> 149
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Enrollment change: A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers (clinicaltrials.gov) - Jul 1, 2014
P1, N=149, Completed, Sponsor: MedImmune LLC
N=60 --> 149 Recruiting --> Completed | N=60 --> 149
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Jun 27, 2014
P3, N=3250, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | N=60 --> 149 Not yet recruiting --> Recruiting
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial: STRATOS1: A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) - Jun 13, 2014
P3, N=3250, Not yet recruiting, Sponsor: AstraZeneca
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers (clinicaltrials.gov) - Apr 17, 2014
P1, N=60, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: A Safety and Efficacy Study of Tralokinumab in Adults With Asthma (clinicaltrials.gov) - Mar 19, 2014
P2, N=689, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting N=452 --> 689
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion: A Safety and Efficacy Study of Tralokinumab in Adults With Asthma (clinicaltrials.gov) - Mar 19, 2014
P2, N=689, Completed, Sponsor: MedImmune LLC
N=452 --> 689 Active, not recruiting --> Completed